Psyence Biomedical (Psyence Biomedical) Preferred Dividends

: $0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Psyence Biomedical's preferred dividends for the six months ended in Mar. 2023 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

Psyence Biomedical Preferred Dividends Historical Data

The historical data trend for Psyence Biomedical's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Preferred Dividends

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Preferred Dividends	-	-	-

Psyence Biomedical Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Psyence Biomedical (NAS:PBM) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024